The Competitive Landscape of GLP-1 Agonists

This chapter examines the distinctions between GLP-1 agonists used for obesity and diabetes, emphasizing key players like Novo Nordisk and Eli Lilly. It also considers the impact of insurance policies on drug choices, investor perspectives, and the future of obesity treatment developments.